| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/14/1999 | US5952374 Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| 09/14/1999 | US5952373 Applying to the skin an effective amount of one or more flavonoids |
| 09/14/1999 | US5952372 Oral administration or topically applying ivermectin in a dosage to eliminate demodex folliculorum mites from hair follicles in affected skin |
| 09/14/1999 | US5952371 Triterpene derivatives with immunosuppressant activity |
| 09/14/1999 | US5952370 Amino ceramide-like compounds and therapeutic methods of use |
| 09/14/1999 | US5952369 Pyrrolidinyl hydroxamic acid compounds and their production process |
| 09/14/1999 | US5952368 5-aroylpyrrol-2-ylmethylarene derivatives |
| 09/14/1999 | US5952367 Method of treating pain cause by bursitis tendinitis arthritis |
| 09/14/1999 | US5952366 Alkyl ether analogs of chlorins having an N-substituted imide ring |
| 09/14/1999 | US5952365 2- 2-(Dimethylamino)ethyl!-8,8-dipropyl-2-azaspiro 4.5!decane dimaleate |
| 09/14/1999 | US5952364 Methods for inhibiting smooth muscle cell proliferation |
| 09/14/1999 | US5952362 2-imidazoline, 2-oxazoline, 2-thiazoline, and 4-imidazole derivatives of methylphenyl, methoxyphenyl, and aminophenyl alkylsulfonamides and ureas and their use |
| 09/14/1999 | US5952361 Compositions |
| 09/14/1999 | US5952360 Admisnistering to a mammal certain phenyl oxazoles or phenyl thiazoles |
| 09/14/1999 | US5952357 Treating diseases of the anterior horn cells |
| 09/14/1999 | US5952356 Treating diabetes in a mammal with an active material and a glucosidase inhibitor |
| 09/14/1999 | US5952354 Enzyme inhibitors of chloesterol ester hydrolase and/or acyl coenzyme a:chloesterol acyltransferase; inhibit the esterification of chloesterol and reduce absorption through the intestine; carbamates of 4-8 membered azacycloalkanols |
| 09/14/1999 | US5952353 To prevent adverse myocardial remodeling secondary to a sustained blood volume overload; administering nedocromil sodium or cromolyn sodium |
| 09/14/1999 | US5952350 Naphthyl compounds and compositions, as estrogen receptor binding agents |
| 09/14/1999 | US5952346 Inhibits the actions of the alzheimer's protein amyloid (beta/a4) in isolated endothelial cells; quinoline derivatives |
| 09/14/1999 | US5952345 Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities |
| 09/14/1999 | US5952344 Treating and control of diseases which represent therapeutic indications for nmda(n-methyl-d-aspertate) receptor subtype specific blokers by administering tetrahydroisoquinoline derivatives |
| 09/14/1999 | US5952343 HIV protease inhibitors |
| 09/14/1999 | US5952342 1,6-naphthyridines effective in treating atherosclerosis, restenosis and psoriasis; anticarcinogenic and -proliferative agents; bactericides |
| 09/14/1999 | US5952340 Use of granisetron for the treatment of postoperative nausea and vomiting |
| 09/14/1999 | US5952339 Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release |
| 09/14/1999 | US5952338 Agent for prophylaxis and treatment of disturbance of visual function |
| 09/14/1999 | US5952337 Remedy and preventive for nervous system disorders |
| 09/14/1999 | US5952334 Carbocyclic compounds |
| 09/14/1999 | US5952333 Inhibitor of tyrosine kinase receptor for treating proliferative disease such as cancer |
| 09/14/1999 | US5952332 Antiviral and cytotoxic compounds from the sponge crambe crambe |
| 09/14/1999 | US5952330 Use of NK-1 receptor antagonists for treating mania |
| 09/14/1999 | US5952329 Contacting cells of tumor with a first chromophore and a second chromophore; exposing said contacted tumor cells to light of a first and second predetermined wavelength and power density and energy level |
| 09/14/1999 | US5952327 Neutral endopeptidase inhibitors; treatment of cardiovascular disorders |
| 09/14/1999 | US5952325 Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists |
| 09/14/1999 | US5952324 Bicyclic oxazine and thiazine oxazolidinone antibacterials |
| 09/14/1999 | US5952322 Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors |
| 09/14/1999 | US5952321 Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| 09/14/1999 | US5952319 Controlling male fertility in mammal |
| 09/14/1999 | US5952318 Treatment of HIV positive patients |
| 09/14/1999 | US5952315 Treating physiological disorders, disorders of the central nervous system such as anxiety, depression and psychosis with an antidepressant |
| 09/14/1999 | US5952313 Composition for antagonizing gram negative bacterial endotoxic activity, comprising a pharmaceutically acceptable carrier and an antagonizing amount of a lipopolysaccharide from a rhizobium etli; treatment of septic shock or toxic shock |
| 09/14/1999 | US5952312 NADH and NADPH therapeutic agents for nasal, sublingual, rectal and dermal administration |
| 09/14/1999 | US5952311 Photosensitizing chemical means for killing tumor cells, wherein tumoricidal activity is activated by absorbing light or energy within a specific wavelength range, and energy donating chemical means for activating photosensitizer |
| 09/14/1999 | US5952309 Method for treating alcoholic liver disease |
| 09/14/1999 | US5952305 Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| 09/14/1999 | US5952298 Cryptophycins |
| 09/14/1999 | US5952295 Composition and method for treatment of inflammatory conditions of the gastro-intestinal tract |
| 09/14/1999 | US5952232 Expandible microparticle intracellular delivery system |
| 09/14/1999 | US5952225 A packaging cell containing a polynucleotide which codes a portion of a selected retrovirus having at least the envelope protein; for producing vectors resistant to complement inactivation by serum; gene therapy |
| 09/14/1999 | US5952199 A protein that contains an immunoglobulin-like domain; antiproliferative/antitumor agents, treatment of rheumatoid arthritis, psoriasis, diabeties, glaucoma, muscular disorders and immune rejection of eye transplants |
| 09/14/1999 | US5952006 Drug preparations for treating impotency |
| 09/14/1999 | US5952005 Particles of a morphine salt coated with a water insoluble barrier layer formed from ethyl cellulose, (meth)acrylic ester copolymers or waxes and a plasticizer; once daily dosage; reduced plasma concentration fluctuation |
| 09/14/1999 | US5952003 Terazosin dosage form capsules containing solid fill which are bioequivalent to a reference liquid-filled terazosin capsule dosage form, but have improved shelf life and are simpler to manufacture |
| 09/14/1999 | US5952001 Preparing pharmaceutical, dermatological or cosmetic preparations for the prevention or treatment of allergic manifestations such as skin allergy, bronchial asthma, or inflammation, or as free radical scavengers |
| 09/14/1999 | US5952000 Transdermal drug delivery system: an active pharmaceutical permeant in a penetration enhancing system of fatty acid esters of lactic acid salts such as sodium lauroyl lactylate and a pressure sensitive adhesive carrier vehicle |
| 09/14/1999 | US5951993 Comprising a lower alcohol and water and solid hydrophobic and hydrophilc emulsifiers; skin disinfection such as presurgical hand preps, patient preps, lotions and presurgical scrub replacement |
| 09/14/1999 | US5951990 Ascorbyl-phosphoryl-cholesterol |
| 09/14/1999 | US5951989 Method for the treatment of dry skin |
| 09/14/1999 | US5951976 Vaccinating a mammal by administering a composition comprising an opsonin-enhanced cell comprising said selected antigen with the provision the opsonin does not bind to a receptor for a fragment of c33 |
| 09/14/1999 | CA2196978C Gelling compositions comprising optically enriched gellants |
| 09/14/1999 | CA2174598C Use of an inhibitor of an hmg-coenzyme-a reductase to prevent aging of the skin or to stimulate the process of epidermal renewal |
| 09/14/1999 | CA2159449C Oesteoblast growth stimulating composition containing pdgf and vitamin d |
| 09/14/1999 | CA2153264C New cyclopropyl derivatives, preparation method thereof and applications |
| 09/14/1999 | CA2150483C Pyrazoles and pyrazolopyrimidines |
| 09/14/1999 | CA2144125C Use of sulfonic acids as antiageing agents in a cosmetic or dermatologic composition |
| 09/14/1999 | CA2130664C Antiparasitic agents |
| 09/14/1999 | CA2118491C Avermectin difluoro derivatives |
| 09/14/1999 | CA2113561C Phosphonic diester derivative |
| 09/14/1999 | CA2071446C Synthetic catalytic oligonucleotide structures |
| 09/14/1999 | CA2006356C Arylpiperazinylbutyl-dihydroindoles and related compounds |
| 09/14/1999 | CA2004177C Readily absorbable drug formulation of nb-818 |
| 09/14/1999 | CA2001044C Oral liquid pharmaceutical compositions of sulindac |
| 09/14/1999 | CA1340743C Compositions for the treatment of ostoporosis in humans |
| 09/14/1999 | CA1340734C Substituted bridged-diazabicycloalkyl quinolone carboxylic acids |
| 09/13/1999 | CA2265412A1 Process for the preparation of azithromycin dihydrate |
| 09/12/1999 | CA2265211A1 Making dosage units using low shear granulation |
| 09/12/1999 | CA2265209A1 Method of preventing allograft rejection |
| 09/12/1999 | CA2231989A1 Therapy for tissue membrane insufficiency |
| 09/12/1999 | CA2231952A1 Inhibition of tumor growth |
| 09/11/1999 | CA2231968A1 Method of producing a nicotine medicament |
| 09/10/1999 | WO1999045391A1 Membrane pore inhibiting agents for treating infection |
| 09/10/1999 | WO1999045108A2 Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines |
| 09/10/1999 | WO1999045102A1 Method for activating natural killer (nk) cells |
| 09/10/1999 | WO1999045055A1 Sulfonated comb polymers and preparations, especially hair cosmetic preparations based on such sulfonated comb polymers |
| 09/10/1999 | WO1999045027A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes |
| 09/10/1999 | WO1999045025A1 Acylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| 09/10/1999 | WO1999045024A1 Cholenic acid amides and pharmaceutical compositions thereof |
| 09/10/1999 | WO1999045023A1 S-SUBSTITUTED 11β-BENZALDOXIME-ESTRA-4,9-DIENE-CARBONIC ACID THIOLESTERS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS |
| 09/10/1999 | WO1999045022A1 20-KETO-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES |
| 09/10/1999 | WO1999045016A2 Novel prodrugs for phosphorus-containing compounds |
| 09/10/1999 | WO1999045015A1 5-imino-13-deoxy anthracycline derivatives, their uses, and processes for preparing them |
| 09/10/1999 | WO1999045011A1 Glycine transport inhibitors |
| 09/10/1999 | WO1999045010A1 Process for synthesizing carbapenem antibiotics |
| 09/10/1999 | WO1999045009A1 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors |
| 09/10/1999 | WO1999045006A1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 09/10/1999 | WO1999045004A1 Nitrate salt of anti-ulcer medicine |
| 09/10/1999 | WO1999044998A1 Novel unsymmetrically substituted carboxylic acid derivatives, method for producing them, and their use as mixed eta/etb-receptor antagonists |
| 09/10/1999 | WO1999044995A1 Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| 09/10/1999 | WO1999044994A1 Meta-azacyclic amino benzoic acid compounds and derivatives thereof being integrin antagonists |